Condition: Spondyloarthritis · Sponsor: Institut Pasteur
This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a multicentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in Spondyloarthritis patients attending the rheumatology department of Cochin, Saint-Antoine, Henri-Mondor hospitals (APHP) and Maison-Blanche Hospital (Reims).
This description comes directly from the study's public registry record.
Lars ROGGE, Dr · +33140613822 · lars.rogge@pasteur.fr
Always discuss trial participation with your own doctor first.
| Hôpital Henri-Mondor, AP-HP - Service de Rhumatologie | Créteil, France | Not Yet Recruiting |
| Hôpital Cochin, AP-HP - Department of Dermatology B | Paris, France | Recruiting |
| Hôpital Saint-Antoine, AP-HP - Service de Rhumatologie | Paris, France | Recruiting |
| Hôpital Maison Blanche - Service de Rhumatologie | Reims, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05290363